Last reviewed · How we verify
lidokaine
lidokaine is a Small molecule drug developed by Bispebjerg Hospital. It is currently FDA-approved. Also known as: Xylocain.
At a glance
| Generic name | lidokaine |
|---|---|
| Also known as | Xylocain |
| Sponsor | Bispebjerg Hospital |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Effect of Perioperative Intravenous Infusion of Lidocaine on the Postoperative Course and the Immune Response in Patients Undergoing Surgery for Colon Cancer - the PILDI Study (PHASE2)
- SPI-guided Analgesia During CEA Under RA (NA)
- Plantar Fasciitis, Operation or Conservative Treatment (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- lidokaine CI brief — competitive landscape report
- lidokaine updates RSS · CI watch RSS
- Bispebjerg Hospital portfolio CI
Frequently asked questions about lidokaine
What is lidokaine?
lidokaine is a Small molecule drug developed by Bispebjerg Hospital.
Who makes lidokaine?
lidokaine is developed and marketed by Bispebjerg Hospital (see full Bispebjerg Hospital pipeline at /company/bispebjerg-hospital).
Is lidokaine also known as anything else?
lidokaine is also known as Xylocain.
What development phase is lidokaine in?
lidokaine is FDA-approved (marketed).
Related
- Manufacturer: Bispebjerg Hospital — full pipeline
- Therapeutic area: All drugs in Other
- Also known as: Xylocain
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing